Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting
- Data demonstrates first-in-class potential as a regenerative treatment of Stress Urinary Incontinence
- Treatment results in muscle regeneration with restored functionality in pre-clinical models
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA engineering technology and lead therapeutic candidate, VMB-100, at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) 2022 Winter Meeting, taking place on 22-26 February 2022 in San Diego, California.
